Gene therapy for adults with hard-to-control epilepsy
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a one-time gene therapy (AMT-260) for adults whose seizures start in one area of the brain (the temporal lobe) and aren't controlled by medication. The goal is to see if it's safe and reduces seizure frequency.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have epilepsy that starts in one small area of your brain (the temporal lobe) and isn't controlled by medication.
- You have at least 2 seizures per month (that affect awareness or spread to both sides) on average over 3 months.
- You take up to 4 anti-seizure medicines and your dose has been stable for at least 1 month.
- MRI scans show damage in your temporal lobe that matches where your seizures start.
- You agree to use effective birth control during the study (if you could become pregnant or father a child).
- You do not have any other major brain conditions, like dementia, brain tumors, or other types of epilepsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests a neural cell therapy (NRTX-1001) for adults whose seizures come from one side of the hippocampus and have not improved with standard seizure medicines. The goal is to reduce seizure frequency and improve seizure control where other treatments have not worked.
This trial tests a gene therapy given directly into the brain to quiet the overactive nerve cells that cause seizures. It's an option for adults with focal epilepsy who are already planning surgery and haven't found relief from medication.
This trial tests a new cell therapy, UX-GIP001, for people whose seizures start in one small area of the brain (the mesial temporal lobe) and are not controlled by at least two seizure medications. The goal is to see if this treatment can safely reduce seizures.
This trial tests a new cell-based treatment for people with epilepsy that has not improved with standard medications. The treatment aims to reduce seizures in patients with a specific type of epilepsy originating from one side of the brain.
This trial tests a new cell therapy (NRTX-1001) for people with epilepsy that starts in both sides of the brain's temporal lobes and doesn't get better with medication. It aims to reduce or stop seizures.
This trial tests a gene therapy given as a nose spray for people with cerebral palsy or HIE. It aims to see if the treatment is safe and helps improve movement over two years.
Hear when a new Mesial Temporal Lobe Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.